Analyst ratings and price targets can significantly influence a stock's performance. In this case, UBS, a reputable financial institution, has given Akero Therapeutics a Buy rating and set a high price target of $83. This suggests that they expect the stock to perform well, which could encourage investors to buy, potentially driving up the stock's price in the short term.